Episode
Episode 188 - Geert Kersten - CEO of CEL-SCI
- Podcast
- The BioHub - by Avetix
- Published
- Jun 11, 2026
- Duration seconds
- 1827
- Processing state
not_requested- Canonical source
- https://podcasters.spotify.com/pod/show/max-brennan4/episodes/Episode-188---Geert-Kersten---CEO-of-CEL-SCI-e3kl2mt
Actions
POST https://stenobird.com/v1/public/podcasts/the-biohub-by-avetix-7252289/episodes/episode-188-geert-kersten-ceo-of-cel-sci/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/the-biohub-by-avetix-7252289/episode-188-geert-kersten-ceo-of-cel-sci.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
In this episode of The BioHub Podcast , Max sits down with Geert Kersten, Chairman and CEO of CEL-SCI Corporation. Geert has led CEL-SCI for nearly three decades, overseeing the development of the company's lead immunotherapy candidate, Multikine, and navigating one of the longest and most challenging journeys in biotech. In this conversation, we discuss the realities of building a biotech company over the long term, the persistence required to advance innovative therapies, and Geert's perspective on today's biotech market. We also explore CEL-SCI's recent clinical progress, the company's long-term vision, and the lessons Geert has learned from spending almost 30 years at the helm of a public biotech company.